BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 22088428)

  • 1. Prognostic value of histologic features of toxic epidermal necrolysis.
    Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
    J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
    Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
    Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.
    Kannenberg SM; Jordaan HF; Koegelenberg CF; Von Groote-Bidlingmaier F; Visser WI
    QJM; 2012 Sep; 105(9):839-46. PubMed ID: 22543685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Gueudry J; Roujeau JC; Binaghi M; Soubrane G; Muraine M
    Arch Dermatol; 2009 Feb; 145(2):157-62. PubMed ID: 19221260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
    Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
    Hosaka H; Ohtoshi S; Nakada T; Iijima M
    J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
    Chen J; Wang B; Zeng Y; Xu H
    Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis.
    Quinn AM; Brown K; Bonish BK; Curry J; Gordon KB; Sinacore J; Gamelli R; Nickoloff BJ
    Arch Dermatol; 2005 Jun; 141(6):683-7. PubMed ID: 15967913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
    Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
    Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.
    Lee HY; Dunant A; Sekula P; Mockenhaupt M; Wolkenstein P; Valeyrie-Allanore L; Naldi L; Halevy S; Roujeau JC
    Br J Dermatol; 2012 Sep; 167(3):555-62. PubMed ID: 22639874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lipowicz S; Sekula P; Ingen-Housz-Oro S; Liss Y; Sassolas B; Dunant A; Roujeau JC; Mockenhaupt M
    Br J Dermatol; 2013 Apr; 168(4):726-32. PubMed ID: 23413807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
    Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
    Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.
    Wanat KA; Anadkat MJ; Klekotka PA
    J Am Acad Dermatol; 2009 Apr; 60(4):589-94. PubMed ID: 19217690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
    Saka B; Kombaté K; Mouhari-Toure A; Akakpo S; Tchangaï-Walla K; Pitché P
    Med Trop (Mars); 2010 Jun; 70(3):255-8. PubMed ID: 20734593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.
    Noe MH; Rosenbach M; Hubbard RA; Mostaghimi A; Cardones AR; Chen JK; Cotliar J; Davis MDP; Dominguez A; Fox LP; Hughey LC; Kaffenberger BH; Kroshinsky D; Kwong BY; Miller DD; Musiek A; Ortega-Loayza AG; Sharon VR; Shinkai K; Summers EM; Wanat KA; Wetter DA; Worswick S; Margolis DJ; Gelfand JM; Micheletti RG
    JAMA Dermatol; 2019 Apr; 155(4):448-454. PubMed ID: 30840032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough.
    Beck A; Quirke KP; Gamelli RL; Mosier MJ
    J Burn Care Res; 2015; 36(1):167-77. PubMed ID: 25559731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
    Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
    Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.